Skip to content

Earnings call

Lupin Q1 FY26 earnings call: Lupin Limited considers a 10% or 15% tariff on generic pharmaceuticals fairly manageable

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

The company considers a 10% or 15% tariff on generic pharmaceuticals fairly manageable. The company is actively recruiting for a Phase 3 study of NaMuscla® in the U.S. and Europe. The company has a share of more than 50% among commercial-covered patients for Tiotropium, while its share among Medicare-Medicaid-covered patients is not strong; efforts to offset some patient costs are beginning to show benefits there, which the company hopes will build over the next couple of quarters. In-licensing share has fallen to 6% from a high of more than 20% at one point, with LOEs and competition contributing to the decline. Operating working capital was INR 7,287 crores as of 30 June, against INR 6,821 crores as of 31 March 2025, equal to 106 days of working capital against 110 days in the previous quarter.

The numbers management gave

Money and capital

  • Net cash was INR 1,239 crores, against INR 310 crores on 31 March 2025.
    Show source
    Net Cash Net cash at INR 1,239 crores as against INR 310 crores on 31 March 2025.
  • Operating working capital was INR 7,287 crores as of 30 June, against INR 6,821 crores as of 31 March 2025, equal to 106 days of working capital against 110 days in the previous quarter. Replaced by a later filing.

What it expects ahead

What management expects

  • The company considers a 10% or 15% tariff on generic pharmaceuticals fairly manageable.
    Show source
    If it is 10%, 15%, I think it should be fairly manageable in any case.
  • The company believes NaMuscla® has a market opportunity between USD 100 million and USD 200 million.
    Show source
    We believe that there's a market opportunity between USD 100 million to USD 200 million.
  • The company indicated that it would grow at least single-digit numbers next year, supported by top-line buoyancy and continued cost focus despite increases in R&D.
    Show source
    This is on the back of, in fact, buoyancy on the top line, and we did indicate that next year also we would grow at least single digit numbers.
  • The company is considering price increases where it has price flexibility, transfers of products to its New Jersey and Coral Springs sites, and IP transfers to the U.S. with contract manufacturing in India to mitigate tariffs; it expects this combination to mitigate a good percentage of the tariff impact.
    Show source
    So, a combination of all of those measures, we expect to be able to mitigate a good percentage of the impact of tariffs.
  • The company expects MFN and other price-reduction measures to have more of an implication for large-value categories with material government and payer spend, and believes its focus on niche products will put it in a better position than large brand companies.
    Show source
    Given our strategy is more on niche products, we believe that we will be in a better position than large brand companies in any case.
  • The company expects NaMuscla® to launch in the U.S. in FY29.
    Show source
    We expect that the product will launch in the U.S in FY29.
Show 18 more statements

What management expects

  • The company expects Liraglutide to take some share from the overall class as the product becomes more affordable with additional competition, particularly among price-sensitive patients.
    Show source
    As the product gets more affordable with additional competition, we would expect that there is some share that Page 10 of 16 August 6, 2025 the product should take from the overall class.
  • Diagnostics business is expected to break even next year.
    Show source
    For example, the diagnostics business is expected to kind of breakeven next year.
  • The company had estimated that it would have additional competition for Tolvaptan in six months; if competition is absent or limited to one competitor instead of two, there may be more upside, and Lupin expects a longer tail even with additional competition because Tolvaptan is a specialty product sold through specialty channels and physicians do not like to change patients repeatedly to a new product.
    Show source
    And in any case, even with additional competition, we expect a longer tail given that it's a specialty product, it's the specialty channels, and the physicians don't like to change patients over and over again to a new product.
  • The company hopes it takes Alvogen and Teva as long as it took Lupin—five years—to get approval for Spiriva.
    Show source
    So, we hope it takes them as long as it took us, five years, to get approval.
  • The company has interest from partners and in a few oncology products in its generic pipeline, and its commercial team is looking at how to leverage these to come to market direct.
    Show source
    And we have interest both from partners as well as with a few of the oncology products that we have on a generic pipeline.
  • The company expects Ranibizumab and Aflibercept to potentially come to market in FY27 and FY28 and to be good drivers of biosimilar growth, given the limited number of competitors.
    Show source
    Plus, on the ophthalmic front, given our ophthalmic portfolio, products like Ranibizumab, Aflibercept that come to market potentially in FY27 and FY28, can be good drivers of growth for biosimilars for us just given the limited number of competitors.
  • The company expects Etanercept in FY29 and expects to be likely one of four; it expects to benefit from the product despite price erosion after IRA or the price erosion expected after IRA negotiation.
    Show source
    Then, in FY29, we expect Etanercept.
  • The company said easing of clinical regulatory requirements and market access will lead other companies to accelerate their biosimilar plans, so Lupin will have to be mindful of its portfolio choices.
    Show source
    We think that with the easing of the regulatory requirements from a clinical standpoint, as well as market access, it certainly will lead other companies also to accelerate their plans on the biosimilars front.
  • The company expects to be in the market with Dulera by the second half of FY27 or early FY28.
    Show source
    And hopefully, by the second half of FY27 or early FY28, we should be in the market with Dulera.
  • The company considers NaMuscla® a sizable opportunity, with a third entrant potentially entering the market in October.
    Show source
    We look at it as a sizable opportunity.
  • The company expects Saxenda® potentially to come to market in the following year; Saxenda® and Victoza® are very similar products.
    Show source
    Also, I'd add to that with Saxenda® potentially coming to market in the following year because they are very similar products, Victoza® and Saxenda®.
  • Generic Victoza® was approved and will be launched in October.
    Show source
    Vinita Gupta: I talked about generic Victoza® just got approved and will be launched in October.
  • Risperdal Consta® will likely get approved in September.
    Show source
    Risperdal Consta® will likely get approved in September.
  • Goal date for Saxenda® approval is into next year, and the company hopes the FDA will expedite approval now that Victoza® has been approved.
    Show source
    I mean, the goal date is into next year.
  • The company sees better than even chances of the injectable launch coming through at that time in India, though there could be a delay risk because no one has the product yet and it is under development across the board.
    Show source
    But I think better than even chances of it coming through at that time.
  • The company is hoping it is at the tail end of the process for Risperdal Consta®. Replaced by a later filing.
    Show source
    But we are hoping that we are at the tail end with Risperdal Consta®.
  • The company expects the oral product in FY27 and the injectable product at the end of FY26. Replaced by a later filing.
    Show source
    Nilesh Gupta: Yes, FY27 for the oral, end of FY26 for the injectable.
  • The company is very optimistic that it will continue its growth momentum this fiscal year and in the next couple of years despite additional competition on key products. Replaced by a later filing.
    Show source
    I just want to reiterate that we are very optimistic that we continue our growth momentum this fiscal year as well as in the next couple of years despite the challenges on additional competition on key pro ducts.

What it is building and selling

Projects and capacity

  • The company is actively recruiting for a Phase 3 study of NaMuscla® in the U.S. and Europe.
    Show source
    Vinita Gupta: We are in active recruitment right now for a Phase 3 study for U.S and Europe.
  • Patient recruitment has been slow in Lupin's Phase 3 trials for NaMuscla® in the U.S., and Lupin is looking to open new centres.
    Show source
    Vinita Gupta: No, it has been patient recruitment that has been slow.
  • The company is actively developing NaMuscla® for the U.S. and other geographies, including Europe.
    Show source
    Plus, rare neurology products like NaMuscla®, we’re actively developing NaMuscla® for the U.S, as well as other geographies, Europe included.
  • The company is developing Certolizumab.
    Show source
    There is Certolizumab that we are developing.
  • The company will soon start clinical development of Certolizumab.
    Show source
    We are going to start development clinical development of Certolizumab soon.
  • The company is developing Pembrolizumab and Nivolumab for India in oncology and immuno-oncology biosimilars.
    Show source
    In India, biosimilars are gaining momentum in our portfolio, especially of oncology and immuno-oncology products like Pembrolizumab and Nivolumab that we are developing for India.
Show 12 more statements

Demand and pricing

  • The company has a share of more than 50% among commercial-covered patients for Tiotropium, while its share among Medicare-Medicaid-covered patients is not strong; efforts to offset some patient costs are beginning to show benefits there, which the company hopes will build over the next couple of quarters.
    Show source
    We have a really good share of the commercial covered patien ts, 50% plus.
  • The company believes the U.S. Liraglutide market is more than half a billion dollars, with a very limited number of players.
    Show source
    Vinita Gupta: We believe it is attractive because it's half a billion dollars plus, and there are very limited number of players right now.
  • Tiotropium market share was at a similar level to the previous quarter.
    Show source
    Vinita Gupta: It has been at a similar level .
  • The company is targeting the entire Glucagon market and will know in the next couple of months how much of a share it can take of the whole market.
    Show source
    Vinita Gupta: So, we're targeting the entire market, but we'll know in the next couple of months how much of a share we can take of the whole market.
  • Amphastar has entered the Albuterol market, and Lupin saw some impact in the quarter that it had anticipated.
    Show source
    Vinita Gupta: So Amphastar has entered the market on Albuterol.
  • Alvogen and Teva have filed on Spiriva, but Lupin said it is hard to say whether they will reach the finish line on a timely basis, given the time involved and their source of supply.
    Show source
    On Spiriva, you have couple of companies that have filed.
  • The company thinks the competitive dynamics for Liraglutide might be a little different than it had earlier expected. Replaced by a later filing.
    Show source
    We think that the competitive dynamics there might be a little bit different than we had earlier expected.

Segments

  • In-licensing share has fallen to 6% from a high of more than 20% at one point, with LOEs and competition contributing to the decline.
    Show source
    It's now down to 6% from a high of more than 20% at one point of time.
  • The company launched Glucagon yesterday and plans to launch Liraglutide by October; it manufactures the products in-house in Nagpur.
    Show source
    Vinita Gupta: So, we have launched Glucagon yesterday and plan to launch Liraglutide by October, and we manufacture the products in-house in Nagpur.
  • Digital, diagnostics, and API CDMO businesses are still evolving and are costing the company money; the company expects them to reach critical mass and become profitable.
    Show source
    They would evolve to a size, to critical mass and they would start making profits.
  • Respiratory biosimilars Mepolizumab and Benralizumab can serve multiple markets and geographies, including the U.S. and Europe, where Lupin has a considerable position with Luforbec®.
    Show source
    We have respiratory biosimilars, Mepolizumab and Benralizumab, that help us serve multiple markets, multiple geographies, not only the U.S, but also Europe, where we have a considerable position now with Luforbec®.
  • The company sees biosimilars as an emerging global platform relevant to the U.S., other developed markets such as Europe, Canada and Australia, as well as India.
    Show source
    So biosimilars is emerging as a platform that is going to have relevance for us in U.S, other developed markets like Europe, Canada, Australia, as well as India.

Risks, rules and outside factors

Rules and policy

  • The company believes not everyone will get to the finish line for Liraglutide approval after the complex approval through the US FDA required responses to a number of tricky queries.
    Show source
    The team really worked hard to respond to a number of pretty tricky queries and we believe that not everyone will get to the finish line.

Everything else said on the call

What management stressed

  • The company intends to in-license products, including GLP-1s, and has a rich funnel.
    Show source
    The focus remains for example, even on GLP-1s, on other products, there is intent to in-license.
  • The company has not shifted gears in biosimilar capital allocation because it already has a handful of products available, including Pegfilgrastim and Onpro®.
    Show source
    So, I'd say that from a capital allocation standpoint, we haven't shifted gears as of yet because we have a handful of products that are available to us already.
  • Over the last three years, Lupin has shifted focus toward its own portfolio, including building its own novel portfolio. Replaced by a later filing.
    Show source
    But the focus in the last three years, I would say, has been moving to focus on our own portfolio, including building our own novel portfolio as well.
  • The company said its primary focus will remain its own portfolio, while it would still want to in-license the right kind of products. Replaced by a later filing.
    Show source
    I think that will remain the primary focus.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Kunal Dhamesha: First question on the top-line growth outlook. I think we have provided outlook on R&D, EBITDA margin. But if you could also provide our expectation for the overall top-line and as well as U.S. and, a related question is, Tolvaptan contribution in Q1 FY26, whether it was a partial contribution or a full quarter contribution?

    Answer, vinita gupta

    Vinita Gupta: So top-line growth for the year, as we have guided earlier, we expect strong double-digit, both for the company and for the U.S. We launched Tolvaptan in late May. So, it was partial quarter. Since it's a specialty product, there was not too much of channel stocking ahead of the launch.

  2. Question

    Kunal Dhamesha: And second one on the India business. The overall India business growth seems to be lower than our formulation business. So has the adjacency which is a small part of the business, has that kind of impacted, or there was a tender business last year that has impacted the growth? How should we think about it?

    Answer, nilesh gupta

    Nilesh Gupta: It's primarily the tender business, it's the institution business, which has impacted. And as we've discussed before, that's lumpy. But by and large, I think we're in a good place on the Global Institution Business as well.

  3. Question

    Kunal Dhamesha: What would be the current drag from the adjacency business like diagnostics, etc., in this quarter particularly?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: So, the impact on our EBITDA would be close to about 1%. They are still evolving and coming up very nicely. So, the long term obviously looks very alluring to us. But clearly, they're still loss-making at this stage.

    Answer, ramesh swaminathan

    Ramesh Swaminathan: For the company as a whole.

    Answer, vivek agrawal

    Vivek Agrawal: Just one clarity on Pegfilgrastim On Body Injectors. So, have you filed or yet to file this product? Which product that you are expecting first? The normal Pegfilgrastim or the OBI one?

    Answer, nilesh gupta

    Nilesh Gupta: I am interested primarily in the OBI. Although the Pegfilgrastim approval will come sooner, we hope to file this during this fiscal year.

    Answer, vivek agrawal

    Vivek Agrawal: One question on the cost front, last year the company saved close to USD 50 million, so it would be great if you can highlight what are the targets for next couple of years, especially in the areas where the company is working on as far as the cost structure. I am trying to understand, margins for the FY27. For FY27, you have guided 24% - 25%. But is it possible that margins in FY27 can dip on the base of FY26, or you can still maintain margins in FY27 on the base of FY26?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: The fact is we are playing for continuous margin expansion. This is on the back of, in fact, buoyancy on the top line, and we did indicate that next year also we would grow at least single digit numbers. But the focus on various items Page 8 of 16 August 6, 2025 of cost is incessant, and you would appreciate, the evidence is there to see. That will kind of provide for margin expansion going forward as well, despite, in fact, the kind of increases that we are seeing on the R&D front. So, we're pretty optimistic about this.

  4. Question

    Saion Mukherjee: One question is on this whole tariff scenario. We may see an announcement in the near term. How are you assessing that? Any colour you can provide given the kind of products that you have or other mitigating measures that can be put in place? Basically, broadly trying to understand how you see the impact, let's say, if you have 10% or 15% kind of tariff being put on generic pharmaceuticals?

    Answer, vinita gupta

    Vinita Gupta: It is of course hard to predict where this lands based on the outcome of the 232 investigations. But I'd say that from a mitigating standpoint, the strategies that we have considered is, one - wherever we can, where we have price flexibility, price increase to offset the impact of tariff. Number two - products where we have the ability to tech transfer into the U.S., certainly in the two sites, both New Jersey as well as Coral Springs. We are looking at a potential to transfer those products. We are also considering some IP transfers that of course will have a capital gains impact, but overall will really benefit us, especially on high value products where we transfer the IP to the U.S and contract manufacture in India. So, a combination of all of those measures, we expect to be able to mitigate a good percentage of the impact of tariffs. If it is 10%, 15%, I think it should be fairly manageable in any case.

    Answer, vinita gupta

    I mean, the question is, is it 25% or the 150% to 200% kind of numbers that have been floated.

    Answer, ramesh swaminathan

    Ramesh Swaminathan: And we should remember, at the end of the day, generics is all about access to medicines, so far as the population is concerned. So, they would also be very conscious of whatever measures that they take so it doesn't impact them too much considering the availability of products in recent times.

  5. Question

    Saion Mukherjee: And the second question is on specialty. You are thinking about it for a while now. Given the changes that we are seeing in the U.S, particularly with respect to the pricing environment, is that changing your thought process around how you should be thinking about going about building the specialty business globally and in the U.S, in particular?

    Answer, vinita gupta

    Vinita Gupta: Strategically, our focus has really been in niche therapy areas where we can really add value. So, areas like respiratory, and niche respiratory products or products that are not large in Asthma-COPD where we compete with big pharma. Plus, rare neurology products like NaMuscla®, we’re actively developing NaMuscla® for the U.S, as well as other geographies, Europe included. So, we expect that the impact of MFN and all of the price reduction measures is likely going to have more of an implication for the large value Page 9 of 16 August 6, 2025 categories, where there is material spend from a government standpoint and a payer standpoint. Given our strategy is more on niche products, we believe that we will be in a better position than large brand companies in any case.

  6. Question

    Saion Mukherjee: On NaMuscla®, if you can update us on the timeline for the U.S, and the market opportunity?

    Answer, vinita gupta

    Vinita Gupta: We are in active recruitment right now for a Phase 3 study for U.S and Europe. We expect that the product will launch in the U.S in FY29. We believe that there's a market opportunity between USD 100 million to USD 200 million.

    Answer, vinita gupta

    Vinita Gupta: No, I think, from a near-term perspective, for the markets that open, we really have a partnered model. We have a partnership in place that will get us into the market. But internal injectable filing is a little bit later, due to the hurdle patent in the U.S. and other major markets.

  7. Question

    Kunal Randeria: I meant Canada. Semaglutide in Canada?

    Answer, nilesh gupta

    Nilesh Gupta: So that will come through partnered, like Vinita said.

  8. Question

    Kunal Randeria: Just to clarify on Mirabegron patent litigation. There are, I think, two patents under active litigation, right? And in one of the patents, I think the outcome depends on one of the other competitors, how their litigation goes. So, is there a likelihood of this drug facing competition by November itself?

    Answer, vinita gupta

    Vinita Gupta: I would say it’s really hard to predict. And anybody who is going through litigation in fall this year also has potentially looking at the timeline of our February trial, which is going to be material for the product.

    Answer, vinita gupta

    Vinita Gupta: So, we have launched Glucagon yesterday and plan to launch Liraglutide by October, and we manufacture the products in-house in Nagpur. Damayanti Kerai: So, why are we waiting until next few months for Liraglutide launch?

    Answer, vinita gupta

    Vinita Gupta: That's the time it takes to really do the validation and get launch quantities together.

  9. Question

    Damayanti Kerai: And how do you see Liraglutide market in the U.S., given the market in general has moved to the new-generation therapies, your Semaglutide and Tirzepatide, etc.? Do you think this market is still attractive?

    Answer, vinita gupta

    Vinita Gupta: We believe it is attractive because it's half a billion dollars plus, and there are very limited number of players right now. As the product gets more affordable with additional competition, we would expect that there is some share that Page 10 of 16 August 6, 2025 the product should take from the overall class. D efinitely the portion that is price sensitive .

  10. Question

    Damayanti Kerai: My next question is on your EBITDA margin. Ramesh, you mentioned there was some 1% drag due to adjacency in India. So similarly, can you quantify if there are other such drag on margins which are right now due to some investment or scale-up which are underway and then you expect these things to go away in few years or few quarters?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: So, what I actually meant was that the adjacencies are costing us some monies because essentially, they are still evolving. Essentially, the digital business, the diagnostics business, the API CDMO business. There is time for them to evolve, they're all start -ups, so to speak. They would evolve to a size, to critical mass and they would start making profits. For example, the diagnostics business is expected to kind of breakeven next year. So that pathway has been very well set.

Show 12 more questions
  1. Question

    Damayanti Kerai: My next question is on your inhaler’s portfolio. On Tiotropium, have you seen any meaningful market share than what we saw last quarter?

    Answer, vinita gupta

    Vinita Gupta: It has been at a similar level .

  2. Question

    Damayanti Kerai: So, what is actually stopping you to gain more market share? Or have you already reached the upper limit, and then we might not see market share gain from here? What are your thoughts on Tiotropium market share gain?

    Answer, vinita gupta

    Vinita Gupta: The team is putting additional efforts around offsetting some of the cost to patients, especially in the Medicare - Medicaid covered patients. That is where we don't have a strong share. We have a really good share of the commercial covered patien ts, 50% plus. But the Medicare - Medicaid is where we are starting to see some benefits, but it's not showing in the numbers as of yet. But we hope that in the next couple of quarters that builds up.

  3. Question

    Neha Manpuria: Given that there is no tentative approval for Tolvaptan, is it fair to assume that we could probably have a longer tail for Tolvaptan versus a usual FTF product?

    Answer, vinita gupta

    Vinita Gupta: We had estimated that we'll have additional competition in six months. But if we don't see it or if it's limited, one instead of two, perhaps there is more of an upside. And in any case, even with additional competition, we expect a longer tail given that it's a specialty product, it's the specialty channels, and the physicians don't like to change patients over and over again to a new product.

  4. Question

    Neha Manpuria: My second question, Glucagon, while your press release mentions just the generic market, the IQVIA market for the generic and the brand, there are also 505(b)(2) in Glucagon. So, would it be fair to assume that our generic would be able to probably even look at that part of the market, the 505(b)(2)? Or you think it's just restricted to the generic products and the brand?

    Answer, vinita gupta

    Vinita Gupta: So, we're targeting the entire market, but we'll know in the next couple of months how much of a share we can take of the whole market.

    Answer, vinita gupta

    Vinita Gupta: So Amphastar has entered the market on Albuterol. We've seen some impact of that you also see in the quarter that we had anticipated. On Spiriva, you have couple of companies that have filed. But just given the time it takes and the source of supply of these companies, it's hard to say, companies like Alvogen and Teva, if they're going to get to the finish line on a timely basis. So, we hope it takes them as long as it took us, five years, to get approval.

  5. Question

    Shyam Srinivasan: Just a second question on biosimilars, since you have been starting to be more vocal, you have done an agreement with Zentiva. So, late entrant, especially in the U.S, not necessarily Europe. But U.S, do you see economics still reasonable, something that you will allocate additional capital to? In opening Page 12 of 16 August 6, 2025 remarks, you talked about on-body versus just the regular one. So, is there is some different entry strategy we might be doing as a follower, second wave? And how do we prepare for the 2029 kind of wave of the next biosimilars?

    Answer, vinita gupta

    Vinita Gupta: So, I think while we are a late entrant, just given the market evolution, we may not be a late entrant. You're just seeing a substantial kind of easing on market access in the last 6-12 months, with Humira and the private labels that have come into market, like the Cordavis label, the Quallent label. They certainly have demonstrated the impact that some of the major customers can have with the private label strategy into the marketplace. So, I'd say that from a capital allocation standpoint, we haven't shifted gears as of yet because we have a handful of products that are available to us already. We have, Pegfilgrastim, we have Onpro®. And we have interest both from partners as well as with a few of the oncology products that we have on a generic pipeline. Our commercial team is also looking at how we can leverage that to come to market direct.

    Answer, vinita gupta

    Plus, on the ophthalmic front, given our ophthalmic portfolio, products like Ranibizumab, Aflibercept that come to market potentially in FY27 and FY28, can be good drivers of growth for biosimilars for us just given the limited number of competitors. Then, in FY29, we expect Etanercept. We're going to be likely one of four. That's still a material product, despite the price erosion that it has seen after IRA, or will see, based on the IRA negotiation. Still a significant product that we expect to benefit from. Then we have a pipeline that we were pursuing. There is Certolizumab that we are developing.

    Answer, vinita gupta

    We are going to start development clinical development of Certolizumab soon. We have respiratory biosimilars, Mepolizumab and Benralizumab, that help us serve multiple markets, multiple geographies, not only the U.S, but also Europe, where we have a considerable position now with Luforbec®. In India, biosimilars are gaining momentum in our portfolio, especially of oncology and immuno-oncology products like Pembrolizumab and Nivolumab that we are developing for India. So biosimilars is emerging as a platform that is going to have relevance for us in U.S, other developed markets like Europe, Canada, Australia, as well as India. So, a global platform that is really promising. We think that with the easing of the regulatory requirements from a clinical standpoint, as well as market access, it certainly will lead other companies also to accelerate their plans on the biosimilars front. So, we'll have to be mindful of the portfolio choices that we make.

    Answer, vinita gupta

    And hopefully, by the second half of FY27 or early FY28, we should be in the market with Dulera. Shashank Krishnakumar: Second question was on the India business. I think in -licensing share obviously has come down to mid-single digits now. How do you sort of look at this going forward? Are we going to double down on our core business? Or will in - licensing still remain a key part of our domestic growth strategy in the medium term?

    Answer, nilesh gupta

    Nilesh Gupta: I think the focus on in-licensing remained all this while. But obviously with the LOE’s and competition, that share has just been coming down. It's now down to 6% from a high of more than 20% at one point of time. The focus remains for example, even on GLP-1s, on other products, there is intent to in-license. There's a rich funnel. But the focus in the last three years, I would say, has been moving to focus on our own portfolio, including building our own novel portfolio as well. We are making good progress on that.

    Answer, nilesh gupta

    I think that will remain the primary focus. Obviously, for the right kind of products, we would still want to in-license.

  6. Question

    Shashank Krishnakumar: I think you mentioned about Phase 3 trials in the U.S. for NaMuscla®. But I think there has been a slight delay in Phase 3. So, is it largely a function of patient recruitment? Or has there been any other challenges there?

    Answer, vinita gupta

    Vinita Gupta: No, it has been patient recruitment that has been slow. So, we are looking to open up some new centres as well.

    Answer, vinita gupta

    Vinita Gupta: For us, strategically, one of our first few injectables, first product out of India. So, it starts creating a reputation for Lupin on the injectable front. And still a sizable product with a third entrant into the market potentially in October. We look at it as a sizable opportunity. Also, I'd add to that with Saxenda® potentially coming to market in the following year because they are very similar products, Victoza® and Saxenda®.

  7. Question

    Tushar Manudhane: With respect to Risperdal Consta®, the goal date being September '25, is this to do with certain queries to be addressed, and which is where the timeline is September '25? If you can just elaborate on that as well.

    Answer, vinita gupta

    Vinita Gupta: It's hard to predict. I remember we had like looked at Tiotropium, we had like at the end 18 queries. But we are hoping that we are at the tail end with Risperdal Consta®. Page 14 of 16 August 6, 2025 Tushar Manudhane: Lastly on Tolvaptan.

  8. Question

    Saion Mukherjee: And the other question is on GLP-1. If I heard you correctly, you said Victoza® generic in September, is that right, for the U.S.?

    Answer, vinita gupta

    Vinita Gupta: I talked about generic Victoza® just got approved and will be launched in October. Risperdal Consta® will likely get approved in September. Saion Mukherjee: And Saxenda® next year?

  9. Question

    Saion Mukherjee: So Saxenda you're expecting - just to clarify, Saxenda you're expecting this year approval, FY26?

    Answer, vinita gupta

    Vinita Gupta: We are hoping that we get approved sooner rather than later. I mean, the goal date is into next year. But now that we've got the Victoza® product approval, we hope that the FDA is going to expedite.

  10. Question

    Saion Mukherjee: Given that you're one of the few companies, which have been able to get an approval for a GLP-1 product, just from a regulatory standpoint, maybe for the U.S., of course, and for other markets, how do you see the hurdle from a regulatory approval perspective? Is there any takeaway for Semaglutide, or these are completely different products? And also, on Semaglutide, if you can Page 15 of 16 August 6, 2025 share your thoughts on India and the other markets and how excited you are about the opportunity next year.

    Answer, vinita gupta

    Vinita Gupta: Yes, I think that it's fair to say Liraglutide was a complex product approval through the US FDA. The team really worked hard to respond to a number of pretty tricky queries and we believe that not everyone will get to the finish line. We think that the competitive dynamics there might be a little bit different than we had earlier expected.

  11. Question

    Saion Mukherjee: You mean FY27 you expect?

    Answer, nilesh gupta

    Nilesh Gupta: Yes, FY27 for the oral, end of FY26 for the injectable. We're a large metabolic player. So obviously, from that perspective, it's very interesting. There will be competition, but I think we should be able to get more than typical share.

  12. Question

    Saion Mukherjee: And do you see the risk of delayed launch from a regulatory standpoint in India for the injectable?

    Answer, nilesh gupta

    Nilesh Gupta: So, nobody's got it yet, right? And it's under development across the board. So, I think there could be. But I think better than even chances of it coming through at that time.

    Answer, vinita gupta

    Vinita Gupta: Thank you, Ravi. I hope we were able to respond to all your questions, number of questions on our portfolio , portfolio evolution, as well as growth prospects. I just want to reiterate that we are very optimistic that we continue our growth momentum this fiscal year as well as in the next couple of years despite the challenges on additional competition on key pro ducts. We believe that we have significant growth drivers in place. The team is very excited and energized to build on the success tha t we have built over the last couple of years and into this fiscal year as well. So, look forward to continuing the momentum and connecting with you again over the next couple of quarters. Thank you.

Questions about this call

When was the Lupin Q1 FY26 earnings call transcript filed?
Lupin filed the transcript with the exchange on 11 Aug 2025. This page is built from that transcript.
What does this page list?
49 statements from the transcript across 7 topics, 9 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 22 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Lupin Q1 FY26 concall: Lupin Limited considers a 10% or 15% tariff on generic pharmaceuticals fairly manageable · DalalOS